REVOLUTIONARY IV INFUSION DEVICE FOR ONCOLOGY Priority Data: #PD2010A000066; International Application No.: PCT/IB2011/050930
PRODUCT TECHNOLOGY AND IP
This is a novel vascular access device, which represents a unique peripheral/central access solution for the administering of IV fluids, medications and in particular for administering hazardous therapeutic agents via venous access.
This device can be envisaged as a modified commonly in use IV infusion set. It represents the only tool that really improves the adequacy of infusion sets and catheters for the administration of chemotherapeutics and other hazardous therapeutics, utilising a patented principle and method not before contemplated in this field.
It is well known that hazardous therapeutics such as cytotoxic drugs, acid or alkaline solutions, hypotonic and hypertonic solutions, cardiovascular agents, antibiotics, antiemetic, bronchodilators, analgesics, antivirals permanently injure vessel walls and limitrophic tissues through permeation during normal administration no matter where the site (central or peripheral). Major injuries may occur during the infusion of vesicant and irritant therapeutics or in cases of extravasation or infiltration.
The current wide extent of suffering and reduction in patient quality of life is presently accepted as an unavoidable collateral consequence of all therapies using these drugs: with this device the medical community will no longer be obliged to inflict suffering and injury on patients as the trade-off for curing another pathology. The aim of our device
to protect patients’ vessels of both circulatory systems, pheripheral and central,
to integrate with specific present devices,
to replace the normally in use IV sets and catheters,
to serve as a mandatory and essential tool for health care professionals for the safe administration of hazardous therapeutics.
The beneficiaries of such a tool
will be mainly cancer patients requiring to undergo chemotherapy, or others in need of infusion therapy involving hazardous drugs such as those listed above.
This novel device
supports catheter reduction initiatives;
lowers or eliminates interventions and associated costs;
reduces injuries to vessels and surrounding tissues
will save thousands of dollars per patient.
reduce catheter related risks both earlier by 6.2–11.2% and later by 6.6% [Vascular access in oncology patients Gallieni, Pittiruti, Biffi 2008];
this IV infusion device is simple to use and manufacture,
preserves both blood-circulating systems
plug & play
non-invasive - requires no surgical operation and no catheterization
more cost-effective than present devices
no leakage and no difficult removal
highly compatible with existing systems and therapies.
The device does not alter therapeutic administration protocols or vary the therapeutic agent concentration, blood volume or administration speed.